{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-25-008086","form_type":"8-K","ticker":"MDCX","cik":"0001997296","company_name":"Medicus Pharma Ltd.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.657868+00:00","generated_at":"2026-05-23T05:17:01.936662+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Medicus Pharma (MDCX) to acquire Antev Ltd. in share exchange; up to $65M in milestones","bullets":["Consideration: 2,666,600 Medicus shares (~19% stake) plus up to US$65M contingent on FDA Phase 2/NDA approvals.","Antev's lead asset Teverelix is a next-generation GnRH antagonist targeting acute urinary retention recurrence and high-CV-risk prostate cancer.","Combined market opportunity estimated at ~$6B annually ($2B AUR, $4B prostate cancer).","Transaction expected to close by end of June 2025, subject to due diligence, definitive agreement, and regulatory approvals.","Antev shares subject to 9-month staggered lock-up and 36-month voting rights in favor of Medicus management."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-25-008086","json":"https://secwatch.observer/filing/0001062993-25-008086.json","markdown":"https://secwatch.observer/filing/0001062993-25-008086.md","text":"https://secwatch.observer/filing/0001062993-25-008086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325008086/0001062993-25-008086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325008086/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:17:01.936662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}